RMC No. 34-2019 explains how sellers of VAT-exempt diabetes, cholesterol, and hypertension medicines must inventory stocks and adjust input tax.

Manufacturers, wholesalers, distributors, and retailers holding unsold diabetes, high-cholesterol, and hypertension medicines as of December 31, 2018 had to inventory those medicines and adjust the related input VAT once the medicines became VAT-exempt beginning January 1, 2019. RMC No. 34-2019 matters because it prevents businesses from continuing to treat input tax on these VAT-exempt medicines as ordinary creditable input tax after the TRAIN Law exemption took effect.

What RMC No. 34-2019 Changed

RMC No. 34-2019 clarified the treatment and reporting requirements for input tax connected with drugs and medicines prescribed for diabetes, high-cholesterol, and hypertension that were purchased on or before December 31, 2018 but remained unsold as of December 31, 2018.

The core rule is direct: because the sale of these medicines became VAT-exempt beginning January 1, 2019 under Section 109(1)(AA) of the National Internal Revenue Code, as amended by Republic Act No. 10963 or the TRAIN Law, the input tax attributable to their VAT-exempt sale cannot be passed on to the buyer. Instead, as the VAT-exempt medicines are sold, the corresponding input tax must be closed to cost or expense.

For businesses searching for VAT exempt medicines TRAIN Law, input tax on diabetes medicines, VAT exempt hypertension medicines, BIR Form 2550Q inventory list, or input tax closed to cost or expense, the practical point is that the VAT exemption changed not only the output VAT treatment of the sale, but also the use of previously recorded input VAT.

Who Is Affected

The affected taxpayers are manufacturers, distributors, wholesalers, and retailers of drugs and medicines prescribed for diabetes, high-cholesterol, and hypertension. The rule applies whether the medicines are imported or locally manufactured, and whether or not the taxpayer had an existing excess input tax balance.

This is important for pharmacies, drugstore chains, pharmaceutical distributors, wholesalers, importers, and manufacturers with covered medicines on hand as of December 31, 2018. Even a taxpayer with no excess input tax was still required to prepare and file the inventory list if it had covered medicines that became VAT-exempt beginning January 1, 2019.

Inventory List Required as of December 31, 2018

RMC No. 34-2019 required an inventory list as of December 31, 2018 for drugs and medicines that became VAT-exempt beginning January 1, 2019. The inventory list had to include all such drugs and medicines on hand, whether imported or locally manufactured, following the prescribed format in Annex “A” of the issuance.

The filing deadline was on or before April 25, 2019. The inventory list had to be filed with the Large Taxpayer Service or the Revenue District Office where the taxpayer was registered, as an attachment to the Quarterly VAT Declaration, BIR Form 2550Q, for the first quarter of 2019.

This makes the inventory list more than an internal accounting schedule. It was a tax reporting document tied to the taxpayer’s first quarter 2019 VAT filing. Affected taxpayers needed to reconcile inventory records, purchase records, input tax records, and VAT filings to ensure that the input tax on covered unsold medicines was properly tracked and deducted from allowable input tax as the exempt sales occurred.

How the Input Tax Must Be Treated

As the VAT-exempt drugs and medicines are sold, the input tax corresponding to the sale must be closed to cost or expense. RMC No. 34-2019 also states that when filing BIR Form 2550M or BIR Form 2550Q, the input tax corresponding to the sale must be deducted from the taxpayer’s allowable input tax.

The illustration in the issuance shows the accounting impact. A taxpayer purchased covered medicines in December 2018 amounting to ₱300,000.00, with input tax of ₱36,000.00. The medicines were sold in January 2019 with a 30% mark-up, resulting in a sale of ₱390,000.00. The taxpayer also had excess input tax credit of ₱150,000.00 as of December 31, 2018.

To record the December 2018 purchase, inventory was recorded at ₱300,000.00 and input tax at ₱36,000.00, with cash or accounts payable of ₱336,000.00. To record the January 2019 VAT-exempt sale, cash or accounts receivable was recorded at ₱390,000.00 and sales or revenue at ₱390,000.00. The cost of sale was recorded at ₱300,000.00 against inventory. The key tax adjustment is the closing of the ₱36,000.00 input tax to cost of sale or expense.

In VAT return reporting terms, the example shows total available input tax of ₱150,000.00 and a deduction from input tax of ₱36,000.00 for input tax on sales to the government or closed to expense, leaving ₱114,000.00 as the remaining input tax figure in the illustration. The commercial result is that the taxpayer cannot use the ₱36,000.00 input tax attributable to the VAT-exempt medicine sale as a continuing VAT credit.

Key Deadlines and Compliance Requirements

The first key date is December 31, 2018, which is the inventory cut-off date. Covered medicines purchased on or before that date and remaining unsold as of that date had to be identified. The second key date is January 1, 2019, when the sale of drugs and medicines prescribed for diabetes, high-cholesterol, and hypertension became VAT-exempt. The third key date is April 25, 2019, the deadline for filing the inventory list as an attachment to the first quarter 2019 BIR Form 2550Q.

Affected taxpayers had to determine the covered medicines on hand, separate imported from locally manufactured medicines where applicable, prepare the required inventory list, file it with the proper Large Taxpayer Service or Revenue District Office, and make the proper accounting and VAT return adjustments when the VAT-exempt medicines were sold.

Penalties and Risk of Non-Compliance

RMC No. 34-2019 does not create a separate special penalty provision in the text of the issuance. However, the compliance risk is significant because the circular requires the inventory list and directs how the related input tax must be treated in BIR Form 2550M or BIR Form 2550Q.

If a taxpayer continues to treat the input tax attributable to VAT-exempt medicine sales as allowable input tax, the BIR may question the VAT return position, require adjustment of input tax credits, and assess the taxpayer based on the ordinary consequences of incorrect VAT reporting under the tax laws. For CFOs and corporate accountants, the practical risk is not merely the missing inventory list; it is the possible overstatement of creditable input tax after the medicines became VAT-exempt.

Practical Steps for Businesses

Businesses dealing in pharmaceutical products should confirm whether they had diabetes, high-cholesterol, or hypertension medicines on hand as of December 31, 2018 and whether the required inventory list was filed with the correct BIR office by April 25, 2019. They should also verify whether the input tax on those medicines was closed to cost or expense when the VAT-exempt sales were made.

Accounting teams should review the VAT returns for the relevant 2019 periods, especially BIR Form 2550Q for the first quarter of 2019 and any BIR Form 2550M or 2550Q where the corresponding sales were reported. The review should focus on whether the input tax attributable to VAT-exempt medicine sales was deducted from allowable input tax, and whether any remaining excess input tax balance was computed after the required adjustment.

For businesses with historical VAT audits, open assessments, due diligence reviews, or tax compliance clean-up projects, RMC No. 34-2019 remains relevant because it provides the BIR’s specific framework for handling input tax connected with the TRAIN Law VAT exemption on covered medicines.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco assists businesses, CFOs, accountants, pharmaceutical companies, distributors, retailers, and in-house counsel in reviewing VAT compliance, preparing BIR submissions, responding to tax audits, and resolving input tax issues arising from changes in VAT law.

If your company handled diabetes, high-cholesterol, or hypertension medicines during the TRAIN Law transition period, or if you need help reviewing VAT-exempt sales and input tax treatment under RMC No. 34-2019, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *